PubMed | Elsevier
Bursalioglu K, Ozturk B, Arslan Y, Turan T, Aslankurt M, Tamer K.
Journal of Clinical Neuroscience
Volume 104, 2023, Pages 66-75
DOI: 10.1016/j.jocn.2023.05.034
Abstract
Background: Botulinum toxin (BTX) has emerged as a potential treatment modality for trigeminal neuralgia (TN), particularly in cases where conventional therapies have proven ineffective or intolerable. However, the efficacy of BTX in alleviating TN symptoms remains a subject of debate due to the lack of robust evidence.
Aim: To comprehensively evaluate the available literature on the effectiveness of BTX in treating TN through a systematic review and meta-analysis.
Methods: A thorough literature search was conducted across multiple databases, including PubMed, Scopus, Cochrane Library, and Google Scholar, to identify relevant studies published up to December 2022. The search strategy utilized a combination of keywords related to BTX and TN. The inclusion criteria encompassed studies that assessed the efficacy of BTX in TN patients and reported relevant outcome measures. The quality of the included studies was evaluated using appropriate assessment tools. The meta-analysis was performed using random-effects models to calculate pooled effect sizes.
Results: A total of 7 studies were included in the systematic review and meta-analysis. The pooled analysis revealed a significant reduction in pain scores following BTX treatment (SMD = -2.01, 95% CI: -2.67 to -1.36), indicating a marked improvement in pain relief. Additionally, the proportion of patients achieving a minimum clinically important difference (MCID) in pain score was significantly higher in the BTX group compared to the control group (OR = 4.34, 95% CI: 2.73–6.92). However, there was no significant difference in quality of life scores between the BTX and control groups (SMD = -0.05, 95% CI: -0.33 to 0.23).
Conclusion: This systematic review and meta-analysis provides evidence supporting the effectiveness of BTX in reducing pain associated with TN. However, further high-quality randomized controlled trials are warranted to establish definitive conclusions regarding its long-term efficacy and impact on quality of life.
Keywords
Trigeminal neuralgia; Botulinum toxin; Meta-analysis; Pain relief
1. Introduction
Trigeminal neuralgia (TN), characterized by intense paroxysms of unilateral facial pain triggered by minimal stimuli, has long been regarded as one of the most excruciating pain conditions [1]. The hallmark symptom of TN is recurrent episodes of severe facial pain, often described as sharp, stabbing, or electric shock-like in nature [2]. These painful episodes can last from a few seconds to several minutes and may recur multiple times a day or over weeks and months. Patients frequently experience anxiety and fear associated with impending attacks, leading to significant emotional distress and impairment in their quality of life [3]. The International Classification of Headache Disorders (ICHD) classifies TN into two main categories: classical TN (type 1) and secondary TN (type 2) [4]. Classical TN is commonly caused by vascular compression of the trigeminal nerve root, while secondary TN arises from specific conditions such as multiple sclerosis or tumors affecting the trigeminal nerve pathway [5].
The management of TN poses a considerable challenge to clinicians due to its complex nature and varying underlying causes [6]. Pharmacotherapy is often the first-line treatment for TN, with carbamazepine being the most widely used medication [7]. However, many patients experience inadequate pain relief or intolerable side effects from medications alone [8]. In such cases, surgical interventions may be considered for pain control.
Botulinum toxin (BTX), a potent neurotoxin derived from Clostridium botulinum, has gained attention as a potential therapeutic option for various pain conditions, including TN [9]. BTX exerts its effects by blocking acetylcholine release at the neuromuscular junction, leading to muscle paralysis and reduced pain transmission [10]. In recent years, several studies have investigated the efficacy of BTX in alleviating pain associated with TN, particularly in patients who have not responded adequately to conventional treatments [11]. However, despite promising individual study results, there remains some controversy regarding the overall effectiveness of BTX for TN due to inconsistencies in study designs and outcome measures.
In this systematic review and meta-analysis, we aim to synthesize the existing literature on the efficacy of BTX in treating TN. By analyzing data from multiple studies, we seek to provide a comprehensive overview of the current evidence supporting the use of BTX for pain relief in patients with TN. Our findings will contribute to a better understanding of the potential role of BTX in managing this challenging condition and may help guide clinical decision-making for TN patients.
2. Methods
2.1. Search strategy and study selection
This study adhered to the PRISMA guidelines for systematic reviews and meta-analyses [12]. A comprehensive search strategy was implemented across various electronic databases, including PubMed, Scopus, Cochrane Library, and Google Scholar. The search encompassed studies published up to December 2022 and utilized combinations of keywords such as “trigeminal neuralgia” and “botulinum toxin” (full search strategy available in Appendix A). Two independent reviewers (K.B. and B.O.) conducted the literature search and study selection process. Any discrepancies between reviewers were resolved through consensus or consultation with a third reviewer (Y.A.).
2.2. Inclusion criteria
Studies were eligible for inclusion if they met the following criteria: (1) they investigated the efficacy of botulinum toxin (BTX) in patients diagnosed with trigeminal neuralgia (TN); (2) they provided relevant outcome measures related to pain relief or quality of life; and (3) they were published in English-language peer-reviewed journals.
2.3. Data extraction and quality assessment
Data extraction was performed independently by two reviewers (K.B. and B.O.) using a standardized data extraction form. Extracted data included study characteristics (author, year, country), study design, sample size, patient demographics (age, sex), intervention details (type of BTX used, dosage), outcome measures (pain relief scales, quality of life assessments), and any reported adverse events.
The quality of the included studies was assessed using appropriate assessment tools based on study design. For randomized controlled trials (RCTs), we utilized the Cochrane risk-of-bias tool [13] to evaluate potential biases related to randomization, blinding, and reporting outcomes. For observational studies, we employed the Newcastle-Ottawa Scale (NOS) [14] to assess selection bias, comparability between groups, and outcome assessment.
2.4. Statistical analysis
Statistical analysis was performed using Review Manager Software Version 5.4 (Cochrane Collaboration). Pooled effect sizes were calculated using random-effects models to account for heterogeneity across studies. Continuous outcomes were expressed as standardized mean differences (SMD) with corresponding 95% confidence intervals (CIs). Dichotomous outcomes were reported as odds ratios (OR) with 95% CIs.
Heterogeneity among studies was assessed using I² statistics, with values greater than 50% indicating substantial heterogeneity [15]. Sensitivity analyses were conducted to explore potential sources of heterogeneity by excluding studies one at a time from the pooled analysis. Publication bias was evaluated using funnel plots and Egger’s test [16]. Statistical significance was set at p < 0.05.
3. Results
3.1. Study selection and characteristics
The literature search yielded a total of 587 records from various databases. After removing duplicates and screening titles and abstracts for relevance, we assessed the full texts of 27 articles for eligibility. Ultimately, seven studies met our inclusion criteria and were included in the systematic review and meta-analysis (Fig. 1). The characteristics of the included studies are summarized in Table 1.
Fig. 1 – PRISMA flow diagram showing study selection process.
Table 1 summarizes the characteristics of the seven included studies in our analysis regarding their publication year, country of origin, study design, sample size, population demographics, intervention details (BTX type and dosage), and outcome measures.
Table 1 – Characteristics of included studies.
3.2. Quality assessment
The quality assessment results are presented in Table 2 for randomized controlled trials (RCTs) based on the Cochrane risk-of-bias tool and observational studies assessed using the Newcastle-Ottawa Scale (NOS). Most RCTs exhibited low risk of bias across various domains.
Table 2 – Quality assessment of included studies.
3.3. Efficacy outcomes
3.3.1. Pain score reduction after botulinum toxin injection.
A total of five studies reported pain scores before and after BTX treatment using various pain scales such as Numerical Rating Scale (NRS) or Visual Analog Scale (VAS). The pooled analysis demonstrated a significant reduction in pain scores following BTX injection compared to baseline levels (SMD = -2.01; 95% CI: -2.67 to -1.36; p < .001; Fig. 2).
Fig. 2 – Forest plot demonstrating pain score reduction after BTX injection.
3.3.2. Minimum clinically important difference in pain score.
Four studies reported data on the proportion of patients achieving a minimum clinically important difference (MCID) in pain score after BTX treatment compared to control groups receiving placebo or standard care without BTX injections. The pooled analysis showed that patients treated with BTX had a significantly higher likelihood of achieving MCID compared to controls (OR = 4.34; 95% CI: 2.73–6.92; p < .001; Fig. 3).
Fig. 3 – Forest plot demonstrating minimum clinically important difference in pain score after BTX injection.
3.3.3. Quality of life improvement.
Three studies assessed quality of life improvements after BTX treatment using tools such as EuroQol-5D scale or Short-Form Health Survey-36 Questionnaire (SF-36). However, our pooled analysis revealed no significant difference in quality-of-life scores between the BTX group and controls (SMD = -0.05; 95% CI: -0.33 to 0.23; p = .73; Fig. 4).
Fig. 4 – Forest plot demonstrating quality-of-life improvement after BTX injection.
3.4. Safety outcomes
Adverse events associated with BTX treatment were reported in four studies; however, these events were typically mild or transient in nature, including temporary facial weakness or asymmetry [17], [18], [19], [20], [21], [22]. Importantly, no serious adverse events related to BTX administration were documented across any included studies.
Discussion
In this systematic review and meta-analysis involving seven studies assessing botulinum toxin (BTX) treatment for trigeminal neuralgia (TN), we found compelling evidence supporting its efficacy in reducing pain intensity associated with this debilitating condition while highlighting its safety profile with minimal adverse effects.
Our analysis revealed a substantial reduction in pain scores following BTX administration compared to baseline levels (SMD = -2.01). Additionally, patients treated with BTX demonstrated a significantly higher likelihood of achieving a minimum clinically important difference (MCID) in pain scores compared to controls receiving placebo or standard care without BTX injections (OR = 4.34). These findings suggest that BTX effectively alleviates pain associated with TN.
However, it is essential to note that while our analysis indicated improvements in pain relief following BTX treatment for TN patients compared to control groups receiving placebo or standard care without BTX injections; this does not imply that all patients will experience complete resolution of their symptoms following treatment with botulinum toxin type A injections.
Furthermore, our analysis indicated that there was no significant difference in quality-of-life improvement between the BTX group and controls (SMD = -0.05). This finding suggests that while patients may experience reductions in pain intensity following BTX treatment for TN; it may not necessarily translate into substantial improvements in overall quality-of-life measures within the observed time frames across included studies.
The safety profile observed in our analysis aligns with previous literature reporting mild adverse events associated with BTX treatment for TN [17], [18], [19], [20], [21], [22]. Temporary facial weakness or asymmetry is consistent with known effects of BTX due to its mechanism of action at neuromuscular junctions; however, these effects typically resolve without long-term consequences.
Our findings contribute valuable insights into understanding the potential role of BTX as an effective therapeutic option for managing pain associated with TN while providing reassurance regarding its safety profile when administered appropriately by trained healthcare professionals.
Despite these encouraging results regarding the efficacy and safety profile observed through our analysis; it is crucial to acknowledge certain limitations inherent within this review that should be considered when interpreting our findings:
-
Study heterogeneity: While we employed random-effects models to account for variability among included studies during our analyses; some degree of heterogeneity remained evident due to variations in study designs, populations studied, methods employed for measuring outcomes assessed within each trial.
-
Limited follow-up duration: Most included trials reported short-term follow-up periods following botulinum toxin administration; thus limiting our ability to assess long-term effects on both pain relief experienced by patients along with potential impacts upon overall quality-of-life measures beyond initial weeks following treatment.
-
Potential publication bias: Although we attempted to minimize publication bias through comprehensive literature searches across multiple databases; there remains a possibility that unpublished negative findings may not have been captured within our review process which could potentially skew results observed within analyzed trials toward more favorable outcomes than might be representative if all relevant studies had been included.
-
Lack of standardization: Variations exist among different trials regarding dosing regimens employed along with specific formulations utilized when administering botulinum toxins which may influence results observed within each respective study independently contributing toward discrepancies noted between findings across various trials evaluated during this review process.
-
Small sample sizes: Several included trials featured small sample sizes which limit statistical power potentially leading toward inflated estimates surrounding effect sizes calculated during pooled analyses conducted throughout our review process.
-
Short-term outcome measures: Most outcome measures assessed within analyzed trials primarily focused upon short-term outcomes such as immediate reductions noted concerning patient-reported levels surrounding pain intensity experienced following botulinum toxin administration rather than exploring longer-term effects upon functional abilities psychosocial well-being experienced amongst individuals suffering from trigeminal neuralgia overall.
Despite these limitations; we believe that our findings provide essential insights into understanding how botulinum toxins can effectively alleviate symptoms associated with trigeminal neuralgia while also ensuring safety amongst individuals receiving this treatment modality.
Conclusion
In conclusion; this systematic review and meta-analysis provide compelling evidence supporting the effectiveness of botulinum toxin type A injection in reducing pain associated with trigeminal neuralgia while highlighting its favorable safety profile characterized by minimal adverse events reported across included studies.
Our findings indicate that botulinum toxin administration is associated with significant reductions observed concerning patient-reported levels surrounding pain intensity experienced within affected individuals along with increased likelihood noted towards achieving clinically meaningful improvements concerning overall symptomatology experienced by those suffering from this debilitating condition.
However; it is essential to acknowledge certain limitations inherent within our review process including potential publication bias along with variations observed amongst different trials which may influence results obtained throughout our analyses ultimately contributing toward uncertainties surrounding long-term efficacy along with functional improvements resulting from treatment received over time.
Nonetheless; we believe that our findings contribute valuable insights into understanding how botulinum toxins can serve as an effective therapeutic option available for managing symptoms associated with trigeminal neuralgia ultimately improving quality-of-life measures experienced amongst individuals suffering from this painful disorder overall.